Fanny Collaud - Genethon, Evry, France

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 76 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Synergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver

Louisa Jauze, Mallaury Vie, Quentin Miagoux, Lucille Rossiaud,Patrice Vidal,Valle Montalvo-Romeral, Hanadi Saliba,Margot Jarrige,Helene Polveche, Justine Nozi, Pierre-Romain Le Brun, Luca Bocchialini,

JCI insightno. 11 (2024)

Cited0Views0WOSBibtex

Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa^−/− mice

Pauline Sellier, Pierre Vidal, Benjamin Bertin,Evelyne Gicquel, Bertil‐Froidevaux,Christophe Georger,Laetitia van Wittenberghe, Armand F. Miranda,Nathalie Danièle,Isabelle Richard,David-Alexandre Gross,Federico Mingozzi,

Journal of Inherited Metabolic Disease (2023)

Cited0Views0Bibtex

Autophagy Induction Improves Dual AAV Vector Efficacy in a Mouse Model of Glycogen Storage Disease Type III

Louisa Jauze, Mallaury Vie, Quentin Miagoux,Margot Jarrige,Patrice Vidal, Maria del Valle Montalvo-Romeral, Lucille Rossiaud, Justine Nozi, Pierre-Romain Le Brun,Jeremy Rouillon,Fanny Collaud, Emilie Bertil-Froidevaux,

MOLECULAR THERAPYno. 4 (2023): 659-660

Cited0Views0Bibtex

Lethality rescue and long-term amelioration of a citrullinemia type I mouse model by neonatal gene-targeting combined to SaCRISPR-Cas9

Michela Lisjak,Alessandra Iaconcig,Corrado Guarnaccia, Antonio Vicidomini, Laura Moretti,Fanny Collaud,Giuseppe Ronzitti,Lorena Zentilin,Andrés F Muro

Molecular therapy. Methods & clinical development (2023): 101103-101103

Cited0Views0WOSBibtex

A novel muscle-specific promoter to improve muscle targeting while reducing liver overload

P. Sellier,P. Vidal, J. Fabergue,M. Gomez,L. van Wittenberghe,A. Miranda, N. Daniele, T. Labella,F. Collaud,F. Mingozzi,G. Ronzitti

HUMAN GENE THERAPYno. 23-24 (2022): A48-A48

Cited0Views0Bibtex

Comparative evaluation of genome editing and RNA interference for substrate reduction therapy in two animal models of glycogenosis

F. Collaud, P. Sellier, J. P. Parada-Zelada, S. Barral, M. Khoja,M. Gomez, N. Zabaleta,L. Van Wittenberghe,A. Miranda, B. Marolleau, G. Tanniou, F. Bordier,

HUMAN GENE THERAPYno. 23-24 (2022): A204-A204

Cited0Views0Bibtex

From AAV virus to AAV vector: characterization of a collection of AAV capsid variants isolated from human liver

T. La Bella, B. Bertin, S. Pezet, S. Astord, J. Nozi, A. Mihaljevic, N. Tedesco,P. Vidal,F. Collaud, T. Marais,S. Imbeaud, J. C. Nault,

HUMAN GENE THERAPY（2022）

Cited0Views0Bibtex

Adeno-Associated Virus Vector Mediated Gene Therapy For Crigler Najjar Syndrome: Preliminary Report Of Safety And Efficacy From The Carecn Clinical Trial

Lorenzo D'Antiga,Ulrich Beuers,Nicola Brunetti-Pierri,Ulrich Baumann,Angelo Di Giorgio,Sem J. Aronson,Aurelie Hubert,Roberta Romano,Norman Junge,Piter Bosma,Mariya Pavlyuk,Philippe Veron,

JOURNAL OF HEPATOLOGY（2021）

Cited2Views0Bibtex

Artificial miRNA-mediated glycogen synthase silencing as effective substrate reduction therapy in glycogen storage diseases mouse models

F. Collaud, P. Sellier, J. P. Parada Zelada, S. Barral, M. Khoja,L. van Wittenberghe,A. Miranda, B. Marolleau, F. Bordier,M. Da Silva, E. Bertil-Froidevaux,S. Jimenez,

HUMAN GENE THERAPY（2021）

Cited0Views0Bibtex

Adeno-associated virus vector mediated gene therapy for Crigler Najjar syndrome: results of safety and efficacy from the dose escalation phase of the CareCN clinical trial

L. D'Antiga, U. Beuers,N. Brunetti-Pierri, U. Baumann,A. Di Giorgio, S. Aronson, A. Hubert, R. Romano, N. Junge,P. Bosma,G. Bortolussi,A. F. Muro,

HUMAN GENE THERAPY（2021）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn